Regulatory News Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC May 08, 2026Vol.52 No.18By Jacquelyn Cobb
Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel May 08, 2026Vol.52 No.18By Paul Goldberg
Letter To The Editor J. Craig Venter’s work was foundational to cancer advancement of the past 25 years May 08, 2026Vol.52 No.18By Joyce Ohm
Sponsored Collaborative work behind the scenes makes cancer breakthroughs possible May 08, 2026Vol.52 No.18By Annaliese Daniels
By adding specialists to USPSTF, Kennedy would reshape the functioning and decisions of the influential health panelRansohoff: “The task force’s job is to describe the evidence fairly, and that’s done best with objective, detached methodologists” May 01, 2026Vol.52 No.17By Claire Marie Porter
Regulatory News FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients“Patients are owed another review.” May 01, 2026Vol.52 No.17By Sara Willa Ernst
Benjamin Ebert, Amy Gladfelter, Stephen Liberles, and Pardis Sabeti are among new members of the National Academy of Sciences May 01, 2026Vol.52 No.17
PodcastThe Directors The Directors: UPMC’s Byrd and Jefferson’s Chapman speak about avoiding catastrophism and using bridge funding to keep labs open“There’s a tightening of the belt, and when the belt gets tightened, it has downstream effects.” April 24, 2026Vol.52 No.16By Claire Marie Porter and Paul Goldberg
NCI At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylinesThere’s “clear evidence that funding is moving and the system is working.” April 24, 2026Vol.52 No.16By Sara Willa Ernst
Problem: Misinformation and stigma prevent uptake of HPV vaccines and screening. Solution: A comic book April 24, 2026Vol.52 No.16By Jacquelyn Cobb
